ALT at a glance
Altimmune, Inc. (ALT, SEC CIK 1326190) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Altimmune, Inc. (ALT) reported revenue of $41,000 (up 105.0% from FY2024) and a net loss of $88.1 million. Diluted EPS was -$1.00.
- As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Altimmune, Inc. (ALT) shares worth $200.1 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by MENZIUSO RICHARD THOMAS on November 18, 2026 of 10,000 shares at $1.42 per share.
- In the last 90 days, ALT insiders reported 4 open-market purchases ($96K) and 0 open-market sales ($0) on Form 4, a net purchase of $96K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $41K
- +105.0% vs prior year
- Insiders · 90 days
- 4 buys · 0 sells
- Net +$96K
- 13F holders
- 29 funds
- $200.1M · +1 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue $0, down 100% YoY from $5,000
- Net loss $31.6M vs $19.0M YoY, operating loss $35.7M vs $20.9M
- Best-performing line: MASH R&D $10.7M, up $6.9M YoY; AUD R&D $1.9M, down $1.4M
- Cash used in operations $82.9M, investments $451.0M at September 30, 2026
- April offering raised $211.1M net; management expects funding for at least twelve months, with tariff and inflation risks ahead
Risk Factors
- No material changes from the March 6, 2026 Form 10-K risk factors
AI summary of the ALT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for revenue, cash position, operating expenses and pipeline updates
Item EX-99.1: Item EX-99.1
- Cash, equivalents and investments $480M as of September 30, 2026, supporting continued late-stage clinical development
- PERFORMA Phase 3 MASH trial advancing, with 52-week topline data expected in 2029
Item 2.03: Creation of a Direct Financial Obligation
- $10.0M Tranche Three draw under $125.0M Hercules Capital loan facility
- Funding tied to achievement of clinical and financial milestones, signaling continued lender support
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expands from nine to eleven directors, adding Peter Greenleaf and Alex Howarth effective November 2, 2026
- Greenleaf brings former CEO and biopharmaceutical commercial leadership experience, strengthening strategic and industry oversight
Item EX-99.1: Item EX-99.1
- Peter Greenleaf and Alex Howarth join the board November 2, 2026, adding late-stage development, commercialization, licensing and M&A expertise
- Three current directors retire at the 2027 annual meeting, marking planned board succession during Altimmune’s transition toward commercialization
Item 7.01: Regulation FD Disclosure
- Press release announces new Board appointments, signaling a change in governance and potential strategic oversight
- Exhibit 99.1 contains appointment details, including director identities and effective terms
AI summaries of ALT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ALT
Don't miss the next ALT filing
- Alerts as it files. A push when ALT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ALT, by share count.
- Ask anything. An AI agent that reads every ALT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MENZIUSO RICHARD THOMAS | Buy | Nov 18, 2026 | 10,000 | $1.42 |
| Durso Jerome Benedict | Buy | Nov 13, 2026 | 30,700 | $1.62 |
| Pisano Wayne | Buy | Nov 13, 2026 | 10,000 | $1.64 |
| WEAVER GREGORY L | Buy | Nov 13, 2026 | 10,000 | $1.62 |
| WEAVER GREGORY L | M | Nov 11, 2026 | 18,750 | - |
| WEAVER GREGORY L | M | Nov 11, 2026 | 18,750 | - |
| WEAVER GREGORY L | F | Nov 11, 2026 | 5,672 | $1.93 |
| Greenleaf Peter | A | Nov 2, 2026 | 160,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $20K | $41K |
| Operating Income | -$95.9M | -$103.2M | -$94.5M |
| Net Income | -$88.4M | -$95.1M | -$88.1M |
| Op. Margin | - | -515860.0% | -230461.0% |
| Net Margin | - | -475295.0% | -214861.0% |
| Balance Sheet | |||
| Total Assets | $210.6M | $139.3M | $279.9M |
| Equity | - | $123.5M | $224.9M |
| ROE | - | -77.0% | -39.2% |
| Per Share | |||
| EPS | $-1.66 | $-1.34 | $-1.00 |
| Cash Flow | |||
| Operating CF | -$75.8M | -$79.8M | -$67.5M |
| CapEx | - | - | $11K |
Source: XBRL data in Altimmune, Inc. (ALT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ALT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 29 | $200.1M |
| Q2 2026 | 28 | $218.1M |
| Q1 2026 | 27 | $138.0M |
| Q4 2025 | 25 | $127.0M |
| Q3 2025 | 24 | $97.3M |
| Q2 2025 | 25 | $81.6M |
| Q1 2025 | 23 | $77.2M |
| Q4 2024 | 20 | $129.4M |
- Two Sigma Investments+1.86M (+78%)
- Vanguard Portfolio Management LLC+777.3K (+11%)
- BlackRock+575.0K (+3%)
- Millennium Management+535.8K (+16%)
- Bank of America Corp+534.2K (+70%)
- State Street Corp−3.74M (-31%)
- AQR Capital Management−1.16M (-95%)
- Vanguard Capital Management LLC−364.8K (-4%)
- Citadel Advisors LLC−289.8K (-29%)
- Citigroup−153.1K (-52%)
- Principal Financial Group+23.4K
- StoneX Group Inc.+16.2K
- U.S. Bancorp+60
- FMR LLC (Fidelity)−749.0K
- Mangrove Partners−239.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 201 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ALT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 8-K | Oct 27, 2026 | - | Analysis | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 8-K | Sep 29, 2026 | - | Analysis | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 13, 2026 | - | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ALT SEC filings: frequently asked questions
Are ALT insiders buying or selling?
In the last 90 days, Altimmune, Inc. (ALT) officers, directors and 10% owners reported 4 open-market purchases worth $96,431 by 4 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ALT stock?
As of September 30, 2026, the largest Altimmune, Inc. (ALT) holders among the 13F filers tracked by SignalX were BlackRock ($59.9 million), State Street Corp ($23.9 million), Vanguard Portfolio Management LLC ($23.2 million), Vanguard Capital Management LLC ($22.3 million), Viking Global Investors ($19.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ALT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Altimmune, Inc. (ALT) reported revenue of $41,000 (up 105.0% from FY2024) and a net loss of $88.1 million. Diluted EPS was -$1.00. The figures come from the XBRL data in the 10-K.
What did ALT report in its latest 8-K?
Altimmune, Inc. (ALT) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest ALT SEC filings?
Altimmune, Inc. (ALT) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 18, 2026.
What is ALT's SEC CIK number?
Altimmune, Inc. (ALT)'s SEC Central Index Key (CIK) is 1326190. EDGAR lists every ALT filing under that number.
Ask anything about ALT
The research agent reads ALT's filings, financials, insider trades and 13F holders, then answers with sources.